AST produces a wide variety of online educational webinars in addition to the Timely Topics in Transplantation (T3) and AST/AJT Journal Club series. These include full educational webinar series available for purchase, and individual free educational webinars sponsored by AST and its Communities of Practice.
Other AST educational webinar series available for purchase:
Other free AST educational webinars:
- BILLING FOR LIVING KIDNEY DONOR CARE: BALANCING COST RECOVERY, REGULATORY COMPLIANCE, AND MINIMIZED DONOR BURDEN (2019) - A Journal Club webinar procuded by the AST Transplant Administration and Quality Management Community of Practice (TxAQM COP)
- LIVE DEBATE: VALGANCICLOVIR 450 MG VS. 900 MG DAILY FOR CMV PREVENTION: A HIGHLY DEBATED TOPIC (2018) - A live debate procuded by the AST Transplant Pharmacy Community of Practice (TxPharm COP)
- CMV IN SOLID ORGAN TRANSPLANT RECIPIENTS (2018) - A webinar sponsored by the Pan American Society for Clinical Virology (PASCV) and the American Society of Transplantation (AST)
- NEW RULES FOR LIVER-KIDNEY ALLOCATION—WHAT YOU NEED TO KNOW (2017) - A topical update from the AST Board of Directors
- OPTIMIZING IMMUNOSUPPRESSION IN LIVER TRANSPLANT PATIENTS - A webinar procuded by the AST Liver and Intestinal Community of Practice (LICOP)
- ASTS/AST UPDATE ON WHITE HOUSE ORGAN SUMMIT COMMITMENTS - An udpate on the White House Organ Summit from the White House Office of Science & Technology Policy
Billing for living kidney donor care: Balancing cost recovery, regulatory compliance, and minimized donor burden.
Originally aired on Tuesday, June 18th, 2019 • Hosted by the Transplant Administration and Quality Management Community of Practice
- Link to the Open Access article.
- Billing for Living Kidney Donor Care: Program Checklist.
- Visit the TxAQM COP Hub for more information on this webinar.
Andrea Tietjen, MBA • Saint Barnabas Medical Center, Livingston, NJ
Krista Lentine, MD, PhD • Saint Louis University Medical Center, Saint Louis, MO
Live Debate: "Valganciclovir 450 mg vs. 900 mg Daily for CMV Prevention: A Highly Debated Topic"
Originally aired on March 22, 2018 • Hosted by the Transplant Pharmacy Community of Practice
Jennifer-Trofe Clark, PharmD, FAST, FCCP, BCPS • Hospital of the University of Pennsylvania, Philadelphia
Steven Gabardi, PharmD, BCPS. FAST, FCCP • Brigham & Women's Hospital, Boston
Camille Nelson Kotton, MD, FIDSA, FAST • Massachusetts General Hospital, Harvard Medical School, Boston
CMV in Solid Organ Transplant Recipients
Sponsored by the Pan American Society for Clinical Virology (PASCV) and the American Society of Transplantation (AST)
New Rules for Liver-Kidney Allocation—What You Need to Know
Originally aired on August 8, 2017
On August 10, 2017 UNOS implemented a new policy regarding simultaneous liver-kidney (SLK) allocation. This new policy, approved by the Board of Directors in June 2016, is the result of over a decade of work drafting proposed language, data analysis, and consensus building. The policy will require liver and kidney programs to report new data on the liver and kidney waiting lists and will also require OPOs to check eligibility status prior to allocating a kidney with a liver.
The objectives of this webinar:
- Participants will understand the three elements of the new policy: 1) SLK medical eligibility criteria; 2) SLK allocation rules; 3) Kidney “safety net”—prioritization for liver recipients on the kidney waiting list in the first year after liver transplant
- Participants will gain knowledge about changes to liver and kidney waiting list functionality around the new policy and documentation required for compliance
Optimizing Immunosuppression in Liver Transplant Patients
While immunosuppression is effective in preventing rejection following LT, it may be sub-optimal for some recipients or too aggressive in others, leading to complications of under- or over-immunosuppression. Many programs have a "one size fits all" approach, leading to standard protocols for everyone and only changed when complications occur (rejection or infection, etc). The field needs to move toward more personalized approaches incorporating clinical characteristics, disease states, diagnoses at the time of transplantation, etc in order to optimize immunosuppression therapy. This four-part webinar series discusses the use of different approaches and the data that support their implementation. Click "Browse Sessions" or "Entire Conference" to view the four sections. Developed by the AST Liver and Intestinal Community of Practice.
ASTS/AST Update on White House Organ Summit Commitments
ASTS and AST are pleased to offer a free one-hour webinar to provide additional information and answer questions related to the call for commitments at the White House Organ Summit in June. The webinar will feature Jennifer Erickson from the White House Office of Science & Technology Policy.
The White House Organ Summit was focused on reducing the wait list for transplantation. During that meeting, a number of organizations announced new initiatives that were innovative and collaborative and intended to address the organ shortage. In follow-up from the Summit, the White House has publicly announced an opportunity for additional commitments focused on transplantation.
This webinar is open to anyone interested in potentially submitting commitments for new transplant initiatives.
Educational Content Disclaimer: The content, information, opinions, and viewpoints contained in educational materials housed on and linked from the AST web site are those of the authors or contributors of such materials. While the AST and its committees take great care to screen the credentials of the contributors and make every attempt to review the contents, AST MAKES NO WARRANTY, EXPRESSED OR IMPLIED, as to the completeness or accuracy of the content contained in the educational materials or on this website. The reader of these materials uses these materials at his or her own risk, and AST shall not be responsible for any errors, omissions, or inaccuracies in these materials, whether arising through negligence, oversight, or otherwise. Reliance on any information appearing on this site is strictly at your own risk. Read the full disclaimer.